Please assess the completion status of the following clinical trial:

Trial Title: Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Patients with progressive or relapsing motor and sensory dysfunction of more than one limb resulting from neuropathy within 2 months prior to the date informed consent is obtained.~* 2. Patients who INCAT score between 2-9. (If the INCAT score is 1 in upper limb, the INCAT score of 2 must be exclusively from leg disability to qualify.)~* 3. Patients who need high-dose intravenous immunoglobulin therapy.~* 4. Patients who continued treatment for CIDP without addition or increase at 30 days before informed consent.~* 5. Patients with greater than or equal to twenty years old at informed consent.~Exclusion Criteria:~* 1. Patients with evidence of myelopathy or demyelination of central nerve~* 2. Patients with evidence of stroke, central nerve system trauma, or persistent neurological deficits due to peripheral neuropathy from other causes（diabetic neuropathy, IgM paraproteinaemia, uraemic neuropathy, toxic neuropathy, hereditary neuropathy）~* 3. Patients with evidence of neuropathy or alcoholic neuropathy or vitamin deficiency neuropathy due to myeloma, lymphoma, sarcoidosis, systemic lupus erythematosus, malignancy, vasculitis, Crow-Fukase syndrome, Sjögren syndrome.~* 4. Patients with multifocal motor neuropathy.~* 5. Patients treated with plasmapheresis at 3 months before informed consent.~* 6. Patients treated with rituximab at 6 months before informed consent.~* 7. Patients treated with high-dose intravenous immunoglobulin（greater than or equal to 1g/kg） at 8 weeks before informed consent.~* 8. Patients treated with intravenous immunoglobulin at 3 weeks before informed consent.~* 9. Patients with history of shock or hypersensitivity for NPB-01.~* 10. Patients with IgA deficiency.~* 11. Patients with malignancy at informed consent.~* 12. Patients with impaired liver function.~* 13. Patients with impaired renal function.~* 14. Patients with cerebro- or cardiovascular disorders.~* 15. Patients with high risk of thromboembolism.~* 16. Patients with hemolytic/hemorrhagic anemia.~* 17. Patients with decreased cardiac function.~* 18. Patients with decreased platelet.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- NPB-01 (Type: EXPERIMENTAL): Intravenous immunoglobulin

Based on this trial design, predict the completion outcome and termination type (if applicable).